From the CEO

Proportion, Balance, and Restraint

February 02, 2023

The restraint to not target solely the major disease groups has provided good proportion and balance for our industry.

Paradigm Shift

January 02, 2023

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.

Of Mice and Men and Armadillos

December 02, 2022

Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.

Voice of Regulators

November 02, 2022

Next year's "FDA Voices" series will cover core topics FDA staff are prioritizing.

Optimizing Quality

October 02, 2022

The 1VQ papers advocate for the idea that certain post-approval changes should be streamlined and expedited.

What Does Cost Mean?

September 02, 2022

While the cost of certain medicines are alarmingly high, they can be considered a bargain measured against a lifetime of traditional costs.

The Stick and Carrot of Quality Management

August 02, 2022

How can we fix the quality manufacturing issues that come with product shortages?

How Can We Come Up Short So Often?

July 02, 2022

Systemic inefficiencies in the pharmaceutical industry undermine problem-solving efforts.

Is AI a Panacea for Pharma’s Productivity Gap?

June 02, 2022

AI could provide solutions to critical manufacturing inefficiencies.

Back to INTERPHEX

May 01, 2022

Spring has returned, and with it comes INTERPHEX.